BSLN Stock Overview
A commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Basilea Pharmaceutica AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 44.45 |
| 52 Week High | CHF 49.00 |
| 52 Week Low | CHF 32.00 |
| Beta | 0.61 |
| 11 Month Change | 11.13% |
| 3 Month Change | 2.77% |
| 1 Year Change | -4.92% |
| 33 Year Change | -6.54% |
| 5 Year Change | -6.42% |
| Change since IPO | -55.99% |
Recent News & Updates
Recent updates
Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now
Apr 18
Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?
Sep 20Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)
Feb 17Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)
Jul 01Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long
Mar 24If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%
Feb 18Shareholder Returns
| BSLN | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 8.4% | 15.5% | 2.6% |
| 1Y | -4.9% | 51.7% | 8.8% |
Return vs Industry: BSLN underperformed the Swiss Biotechs industry which returned 48.5% over the past year.
Return vs Market: BSLN underperformed the Swiss Market which returned 9.2% over the past year.
Price Volatility
| BSLN volatility | |
|---|---|
| BSLN Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 1.7% |
Stable Share Price: BSLN has not had significant price volatility in the past 3 months.
Volatility Over Time: BSLN's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 156 | David Veitch | www.basilea.com |
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections.
Basilea Pharmaceutica AG Fundamentals Summary
| BSLN fundamental statistics | |
|---|---|
| Market cap | CHF 538.78m |
| Earnings (TTM) | -CHF 652.00k |
| Revenue (TTM) | CHF 149.02m |
3.6x
P/S Ratio-826.4x
P/E RatioIs BSLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BSLN income statement (TTM) | |
|---|---|
| Revenue | CHF 149.02m |
| Cost of Revenue | CHF 124.90m |
| Gross Profit | CHF 24.12m |
| Other Expenses | CHF 24.78m |
| Earnings | -CHF 652.00k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.054 |
| Gross Margin | 16.19% |
| Net Profit Margin | -0.44% |
| Debt/Equity Ratio | 570.0% |
How did BSLN perform over the long term?
See historical performance and comparison